GoAI
Get started
Zhengye Biotechnology Holding Limited logo

Zhengye Biotechnology Holding Limited

ZYBT

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Regular session

$1.9612

−$0.0788 · -3.86%

Aug 24, 10:00 AM ET

ZYBT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

45

Fair Value

Momentum

21

Weakening

Sentiment

49

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Songlin Song
Listed since
Jan 7, 2025
Employees
269

Market position

Day range

Current $1.9612

52-week range

Current $1.9612

Open
$2.00
Previous close
$2.04
Volume
22.76K
0.01× average
Average volume
3.86M
Average daily volume
Market cap
92.94M USD
Beta
-2.69
Market reference 1
50-day average
$1.3425
+46.09% above average
200-day average
$1.2449
+57.53% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
405.51M CNY
P/E (TTM)
-8.85×
P/B (TTM)
2.5×
P/S (TTM)
7.8×
EV / EBITDA
-9.54×
Earnings yield
-18.33%
Free cash flow yield
0.18%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
8.30%
Operating margin
-77.04%
Net margin
-89.05%
Return on equity
-27.93%
Return on assets
-15.99%
Return on invested capital
-17.87%

Financial health

Debt / equity
0.3×
Current ratio
1.14×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends73%25%-24%-72%Gross margin, FY2021: 58.58%Gross margin, FY2022: 58.98%Gross margin, FY2023: 61.35%Gross margin, FY2024: 48.99%Gross margin, FY2025: 20.51%Operating margin, FY2021: 24.47%Operating margin, FY2022: 25.29%Operating margin, FY2023: 21.25%Operating margin, FY2024: 8.82%Operating margin, FY2025: -58.66%Net margin, FY2021: 18.20%Net margin, FY2022: 17.96%Net margin, FY2023: 14.86%Net margin, FY2024: 6.07%Net margin, FY2025: -59.97%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 58.58%. Gross margin FY2022 58.98%. Gross margin FY2023 61.35%. Gross margin FY2024 48.99%. Gross margin FY2025 20.51%. Operating margin FY2021 24.47%. Operating margin FY2022 25.29%. Operating margin FY2023 21.25%. Operating margin FY2024 8.82%. Operating margin FY2025 -58.66%. Net margin FY2021 18.20%. Net margin FY2022 17.96%. Net margin FY2023 14.86%. Net margin FY2024 6.07%. Net margin FY2025 -59.97%.

Income trends

Revenue

116.36M CNY-37.56%

Operating income

−68.25M CNY−84.69M CNY

Net income

−69.78M CNY−81.1M CNY
Income trends across reported periods293.27M CNY161.25M CNY29.23M CNY−102.79M CNYRevenue, FY2021: 214.07M CNYRevenue, FY2022: 260.27M CNYRevenue, FY2023: 211.65M CNYRevenue, FY2024: 186.36M CNYRevenue, FY2025: 116.36M CNYOperating income, FY2021: 52.38M CNYOperating income, FY2022: 65.83M CNYOperating income, FY2023: 44.99M CNYOperating income, FY2024: 16.44M CNYOperating income, FY2025: −68.25M CNYNet income, FY2021: 38.96M CNYNet income, FY2022: 46.74M CNYNet income, FY2023: 31.46M CNYNet income, FY2024: 11.31M CNYNet income, FY2025: −69.78M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 214.07M CNY. Revenue FY2022 260.27M CNY. Revenue FY2023 211.65M CNY. Revenue FY2024 186.36M CNY. Revenue FY2025 116.36M CNY. Operating income FY2021 52.38M CNY. Operating income FY2022 65.83M CNY. Operating income FY2023 44.99M CNY. Operating income FY2024 16.44M CNY. Operating income FY2025 −68.25M CNY. Net income FY2021 38.96M CNY. Net income FY2022 46.74M CNY. Net income FY2023 31.46M CNY. Net income FY2024 11.31M CNY. Net income FY2025 −69.78M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue116.36M CNY186.36M CNY211.65M CNY260.27M CNY214.07M CNY
Cost of goods sold92.49M CNY95.06M CNY81.8M CNY106.75M CNY88.67M CNY
Gross profit23.87M CNY91.3M CNY129.86M CNY153.52M CNY125.39M CNY
Research and development18.01M CNY12.79M CNY11.9M CNY13.42M CNY11.37M CNY
Selling, general, and administrative74.92M CNY63.84M CNY66.63M CNY63.56M CNY58.19M CNY
Operating expenses92.12M CNY74.86M CNY84.87M CNY87.69M CNY73.01M CNY
Interest income96K CNY231K CNY312K CNY114K CNY112K CNY
Interest expense3.4M CNY4.04M CNY4.42M CNY2.84M CNY1.05M CNY
Depreciation and amortization25.96M CNY24.16M CNY23.91M CNY18.8M CNY16.01M CNY
Operating income−68.25M CNY16.44M CNY44.99M CNY65.83M CNY52.38M CNY
Net income−69.78M CNY11.31M CNY31.46M CNY46.74M CNY38.96M CNY

Company facts updated Aug 24, 2026.

ZYBT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ZYBT

research.disclaimer